Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 13, 2023 7:21pm
241 Views
Post# 35336282

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China
March 13, 2023 - "Unlike some of his pharma CEO peers who have lambasted the new law, Pfizer CEO Albert Bourla told investors on a call this morning that there are two specific factors pertaining to the IRA that will actually help with the combo of Pfizer and Seagen moving forward:
 
(1) The $2,000 out-of-pocket cap for seniors, which takes effect in 2025 and will mean that more of those on Medicare will be able to access expensive cancer drugs like those developed by Seagen. All four of Seagen’s currently marketed products have list prices of more than $100,000 per year.

(2) All but one of Seagen’s currently marketed drugs are biologics, which means longer exclusivity than small molecule drugs (13 years vs. nine years) under the IRA, prior to the government beginning its negotiations."


https://endpts.com/pfizer-ceo-points-to-ira-as-a-factor-that-made-seagen-an-attractive-target/
<< Previous
Bullboard Posts
Next >>